Lifespan Rhode Island Hospital

Providence, RI
(888) 850-0650

Sorting 2 by

Not yet accepting

DREAMM-10

A Phase 3, Randomized, Open-label Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
Learn more
  • Antibody Drug Conjugate (ADC)
  • BCMA
  • Phase 3

Accepting patients

IDP-023

Phase 1/2 Study of IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
Learn more
  • Natural Killer Cells (Allogeneic)
  • Phase 1/2